Award Number: DAMD17-98-1-8109

TITLE: Chemomodulation of Doxorubicin Pharmacodynamics

PRINCIPAL INVESTIGATOR: Rajagopalan Sridhar, Ph.D.

CONTRACTING ORGANIZATION: Howard University
                        Washington DC, 20059

REPORT DATE: October 1999

TYPE OF REPORT: Annual

PREPARED FOR: U.S. Army Medical Research and Materiel Command
                Fort Detrick, Maryland  21702-5012

DISTRIBUTION STATEMENT: Approved for public release
distribution unlimited

The views, opinions and/or findings contained in this report are those of the author(s) and should not be construed as an official Department of the Army position, policy or decision unless so designated by other documentation.
REPORT DOCUMENTATION PAGE

Public reporting burden for this collection of information is estimated to average 1 hour per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing this collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden to Washington Headquarters Services, Directorate for Information Operations and Reports, 1215 Jefferson Davis Highway, Suite 1204, Arlington, VA 22202-4302, and to the Office of Management and Budget. Paperwork Reduction Project (0704-0188), Washington, DC 20503.

1. AGENCY USE ONLY (Leave blank)
2. REPORT DATE
   October 1999
3. REPORT TYPE AND DATES COVERED
   Annual (30 Sep 98 - 29 Sep 99)

4. TITLE AND SUBTITLE
   Chemomodulation of Doxorubicin Pharmacodynamics

6. AUTHOR(S)
   Rajagopalan Sridhar, Ph.D.

7. PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES)
   Howard University
   Washington DC, 20059
   e-mail:
   sridhar_howard@hotmail.com

9. SPONSORING / MONITORING AGENCY NAME(S) AND ADDRESS(ES)
   U.S. Army Medical Research and Materiel Command
   Fort Detrick, Maryland 21702-5012

12a. DISTRIBUTION / AVAILABILITY STATEMENT
   Approved for public release
distribution unlimited

13. ABSTRACT (Maximum 200 Words)
   This project aims to develop improved strategies for using doxorubicin in the treatment of multidrug resistant advanced breast cancer while simultaneously minimizing the risk of cardiotoxicity. The wild type and multidrug resistant MCF7 human breast cancer cells were characterized and the HPLC methods standardized for use in pharmacokinetic studies. Electron paramagnetic resonance was utilized to detect free radical production by MCF-7 and MCF-7/ADR cells during doxorubicin metabolism. The interaction of tamoxifen with doxorubicin was investigated in vitro. Tamoxifen potentiated the cytotoxicity of doxorubicin towards multidrug resistant MCF-7/ADR cells but not the wild type MCF-7 cells. The wild type MCF-7 and its multidrug resistant variant cells yielded different amounts of free radicals (as judged by spin trapping experiments) when incubated with doxorubicin. The antiestrogen tamoxifen did not affect free radical production from doxorubicin. Interpretation of these results was complicated by the fact that the cell viability differed considerably in the two cell types upon treatment with doxorubicin. Tamoxifen acted as an antioxidant and inhibited free radical initiated lipid peroxidation in cardiac and hepatic microsomal preparations. Tamoxifen may reverse multidrug resistance and exert its antioxidant properties to protect against cardiac tissue damage.

14. SUBJECT TERMS
   Breast Cancer

17. SECURITY CLASSIFICATION OF REPORT
   Unclassified

18. SECURITY CLASSIFICATION OF THIS PAGE
   Unclassified

19. SECURITY CLASSIFICATION OF ABSTRACT
   Unclassified

15. NUMBER OF PAGES 23
16. PRICE CODE
17. SECURITY CLASSIFICATION OF REPORT
   Unclassified
18. SECURITY CLASSIFICATION OF THIS PAGE
   Unclassified
19. SECURITY CLASSIFICATION OF ABSTRACT
   Unclassified
20. LIMITATION OF ABSTRACT
   Unlimited

NSN 7540-01-280-5500

Standard Form 298 (Rev. 2-89)
Prescribed by ANSI Std. 239-18
298-102
FOREWORD

Opinions, interpretations, conclusions and recommendations are those of the author and are not necessarily endorsed by the U.S. Army.

_____ Where copyrighted material is quoted, permission has been obtained to use such material.

_____ Where material from documents designated for limited distribution is quoted, permission has been obtained to use the material.

_____ Citations of commercial organizations and trade names in this report do not constitute an official Department of Army endorsement or approval of the products or services of these organizations.

✓ In conducting research using animals, the investigator(s) adhered to the "Guide for the Care and Use of Laboratory Animals," prepared by the Committee on Care and use of Laboratory Animals of the Institute of Laboratory Resources, national Research Council (NIH Publication No. 86-23, Revised 1985).

✓ For the protection of human subjects, the investigator(s) adhered to policies of applicable Federal Law 45 CFR 46.

_____ In conducting research utilizing recombinant DNA technology, the investigator(s) adhered to current guidelines promulgated by the National Institutes of Health.

_____ In the conduct of research utilizing recombinant DNA, the investigator(s) adhered to the NIH Guidelines for Research Involving Recombinant DNA Molecules.

_____ In the conduct of research involving hazardous organisms, the investigator(s) adhered to the CDC-NIH Guide for Biosafety in Microbiological and Biomedical Laboratories.

Rajagopalan Smith  6-30-2000

PI - Signature  Date
# Table of Contents

<table>
<thead>
<tr>
<th>Section</th>
<th>Title</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>I</td>
<td>Front Cover</td>
<td>1</td>
</tr>
<tr>
<td>II</td>
<td>SF298 Form</td>
<td>2</td>
</tr>
<tr>
<td>III</td>
<td>Foreword</td>
<td>3</td>
</tr>
<tr>
<td>IV</td>
<td>Table of Contents</td>
<td>4</td>
</tr>
<tr>
<td>V</td>
<td>Introduction</td>
<td>5</td>
</tr>
<tr>
<td>VI</td>
<td>Body</td>
<td>6</td>
</tr>
<tr>
<td>VII</td>
<td>Key Research Accomplishments</td>
<td>7</td>
</tr>
<tr>
<td>VIII</td>
<td>Reportable Outcomes</td>
<td>7</td>
</tr>
<tr>
<td>IX</td>
<td>Conclusions</td>
<td>7</td>
</tr>
<tr>
<td>X</td>
<td>References</td>
<td>8</td>
</tr>
<tr>
<td>XI</td>
<td>Appendices</td>
<td>9-23</td>
</tr>
</tbody>
</table>
V. INTRODUCTION

The anti-cancer drug doxorubicin (adriamycin) causes severe adverse effects at high doses and loses its efficacy against multidrug resistant tumors including breast cancer. Potentially fatal cardiotoxicity can develop in patients when the cumulative dose of the drug exceeds 450 mg/m². For optimum use of doxorubicin it is necessary to overcome multidrug resistance of tumor with simultaneous protection against cardiotoxicity. Cardiotoxicity may result from the tendency of doxorubicin and its metabolites to accumulate in the heart and trigger free radical mediated injury (1-3). At present, R-verapamil, tamoxifen, raloxifene and toremifene and dipyridamole are being considered as chemosensitizers for reversing tumor resistance to doxorubicin. It is important to identify and avoid conditions under which they preferentially sensitize the tumor without subjecting the heart to the deleterious effects. Free radicals are known to induce apoptosis. If free radicals are the cause of cardiotoxicity, then R-verapamil, tamoxifen, toremifene, raloxifene and dipyridamole should protect the heart by virtue of their anti-peroxidant action. If apoptosis is the cause of cardiac injury then the alleged anti-apoptotic action of these chemicals should be beneficial to the heart. If the cardiotoxicity is the result of altered kinetics and metabolism of doxorubicin to the more toxic doxorubicinol, then certain metabolic inhibitors would afford protection. Apoptosis in the tumor is desirable, whereas apoptosis in the heart is detrimental. Methods for decreasing the free radical burden in the heart and preventing the accumulation of doxorubicin and its metabolites in the heart may improve the clinical usefulness of doxorubicin. This may be achievable because the antitumor action of doxorubicin may occur through inhibition of DNA topoisomerase with minimal involvement of free radicals. The mechanisms involved in the actions of these pharmacologically diverse compounds may hold valuable clues for improved cancer therapy and protection against cardiotoxicity. The specific aims of the project are:

#1: To determine if R-verapamil, tamoxifen, toremifene, raloxifene and dipyridamole alter the metabolic and pharmacokinetic profiles of doxorubicin in athymic nude mice with multidrug resistant MCF-7 human tumor xenografts. High pressure liquid chromatography (HPLC) will be utilized to measure the concentration of doxorubicin, doxorubicinol and the chemomodulator in blood, tumor, heart, kidneys and liver of mice. The extent of lipid peroxidation and the concentration of reduced glutathione will be determined in heart and liver tissue by standard biochemical assays.

#2: To determine if R-verapamil, tamoxifen, toremifene, raloxifene and dipyridamole have differential effects on programmed cell death (apoptosis) in cardiac tissue compared to the tumor. The extent of apoptosis in heart tissue and tumor will be assayed in situ by histological methods and by DNA laddering assays in order to correlate cardiac damage with extent of apoptosis.

#3: To apply the electron spin resonance (ESR) technique of spin trapping to compare the influence of R- and S-verapamil on doxorubicin-induced free radical formation in vitro and in vivo. Alpha-(2,4,6-trimethoxyphenyl) N-tert-butylnitrone (TMeOPBN) will be administered to mice for in vivo studies and TMeOPBN and 5,5-dimethylpyrrole N-oxide (DMPO) will be used for in vitro experiments with cardiac microsomes and mitochondria isolated from animals in the different treatment groups. The long term goal is to find safer methods of treating multidrug resistant advanced breast cancer with doxorubicin while preventing cardiotoxic side effects of treatment.
VI  BODY

The HPLC techniques have been developed and the necessary quality control measures have been established. These will be directly applicable to pharmacokinetic studies. A standard curve was generated for quantitative analysis of doxorubicin using daunomycin as an internal standard (Figure 1). The reproducibility of the method was also tested (Table 1 and Table 2).

Flow cytometry was used to characterize the cell lines with respect to the presence of the protein associated with multidrug resistance. As expected, the protein associated with multidrug resistance was found only in MCF-7/ADR cells but not in wild type MCF-7 human breast cancer cells.

Since multidrug resistance is associated with an ATP binding permeability glycoprotein (Pgp 170), the influence of glucose on the growth of the two cell lines was examined. The two cells differed in their response to high levels of glucose (Figure 2). Increasing the glucose concentration in the medium from 5 mM to 25 mM was without effect on MCF-7/ADR cells, but stimulated further growth of MCF-7 cells. This may have some bearing on the growth and progression of tumors in diabetic individuals.

The cell lines were further characterized in terms of their sensitivity to doxorubicin in the presence and absence of tamoxifen (Figures 3-6 and Table 3). Isobologram analysis revealed synergistic interaction of doxorubicin with tamoxifen in the case of MCF-7/ADR but not MCF-7 cells (Figures 5 and 6).

Electron spin resonance (ESR) techniques were utilized to study free radical production in cells treated with doxorubicin. The formation of semiquinone free radical from doxorubicin was detected in anaerobic incubations of cells (Figure 7). The spin trap DMPO was utilized to detect the formation of hydroxyl free radicals by cells incubated with doxorubicin and DMPO under aerobic conditions (Figure 8). The dose of doxorubicin needed for demonstrating free radical production was quite cytotoxic and comparison of the results from the drug sensitive MCF-7 and the drug resistant MCF-7/ADR cells was further complicated by the differences in tolerance to doxorubicin.

The ability of tamoxifen to inhibit microsomal lipid peroxidation was studied using liver and cardiac microsomes (Figures 9-11).

The animal studies have been delayed. However, we have grown MCF-7/ADR cells as solid tumor xenografts in nude mice as part of another ongoing project dealing with in vivo phosphorus nuclear magnetic resonance spectroscopy. We will initiate tumor transplantation for pharmacokinetic studies and apoptosis assays in the latter half of the second year of the project and complete the experiments by the end of the third year.
VII. KEY RESEARCH ACCOMPLISHMENTS

HPLC method for measuring doxorubicin content in biological samples has been standardized.

MCF-7 and MCF-7/ADR cells have differ in their growth patterns in RPMI medium with normal (5 mM) and high (25 mM) glucose levels.

MCF-7 and MCF-7/ADR cells metabolize doxorubicin to the corresponding semiquinone free radical. However, the concentration of doxorubicin used to demonstrate this results in reproductive cell death of the cells. The semiquinone free radical was observed under anaerobic conditions. Including 5,5-dimethylpyrroline-N-oxide (DMPO) as a spin trap enabled the detection of hydroxyl radical in aerobic incubation mixtures.

Tamoxifen inhibited doxorubicin stimulated lipid peroxidation in both liver and cardiac microsomes.

Tamoxifen by itself causes reproductive cell death. Tamoxifen interacts synergistically with doxorubicin to cause reproductive cell death in MCF-7/ADR cells, but the interaction is only additive in the case of wild type MCF-7 cells.

VIII. REPORTABLE OUTCOMES

Funded proposal: “Import of Poly ADP-Ribosylation and Free Radical Stress in Ataxia-Telangiectasia (A-T) Heterozygous Human Mammary Epithelial Cells (HMEC)”
Funding Agency: Marshall Space Flight Center, NASA, Huntsville, AL.
Principal Investigator: Rajagopalan Sridhar, 15% time and effort.
Project period: 09/01/99 to 08/31/01.

IX. CONCLUSIONS

A robust analytical method has been established for carrying out pharmacokinetic studies on tumor bearing mice. The formation of free radicals during cellular metabolism of doxorubicin has been demonstrated. However, the conditions necessary for demonstrating free radical formation also caused extensive cell death. Tamoxifen is an efficient antioxidant which interacts synergistically with doxorubicin to kill multidrug resistant MCF-7/ADR cells. This has to be confirmed in vivo using solid tumor xenografts of MCF-7/ADR cells in nude mice. This will be accomplished in the next phase of the project. Raloxifene and toremifene will also be tested in vivo along with tamoxifen. Our experiments underscore the importance of glucose levels in modulating the proliferation rate and cytotoxic response of cells.
X. REFERENCES


8
XI. APPENDICES

#1 Figure 1  Calibration curve for HPLC analysis of doxorubicin
#2 Table 1  Intra-day and inter-day reproducibility of HPLC analysis of doxorubicin
#3 Table 2  Efficiency of acid extraction method for recovery of doxorubicin from mouse plasma
#4 Figure 2  The influence of glucose on the proliferation of MCF-7 and MCF-7/ADR cells in culture
#5 Figure 3  Survival curves for MCF-7 cells treated with graded concentrations of doxorubicin with and without tamoxifen
#6 Figure 4  Survival curves for MCF-7/ADR cells treated with graded concentrations of doxorubicin with and without tamoxifen
#7 Table 3  Enhancement of doxorubicin toxicity by tamoxifen
#8 Figure 5  Isobologram analysis of cell survival data on MCF-7 cells
#9 Figure 6  Isobologram analysis of cell survival data on MCF-7/ADR cells
#10 Figure 7  Comparison of doxorubicin semiquinone free radical production in during anaerobic metabolism of doxorubicin by MCF-7 and MCF-7/ADR cells
#11 Figure 8  Comparison of hydroxyl free radical production in aerobic incubations of MCF-7 and MCF-7/ADR cells containing the spin trap (DMPO) and doxorubicin with and without tamoxifen
#12 Figure 9  Inhibition of cardiac microsomal lipid peroxidation by tamoxifen
#13 Figure 10  Influence of tamoxifen on doxorubicin induced lipid peroxidation in liver microsomes
#14 Figure 11  effect of doxorubicin concentration on microsomal lipid peroxidation
Figure 1: Calibration Curve for HPLC Analysis of Doxorubicin

Absorbance Ratio (DOX/Daun) vs. Concentration of DOX (ng/ml)

200 150 100 50 0

0 1 2 3

Concentration of DOX (ng/ml)
### APPENDIX # 2

<table>
<thead>
<tr>
<th>Concentration of Doxorubicin (ng/ml)</th>
<th>Intra-day</th>
<th>Inter-day</th>
</tr>
</thead>
<tbody>
<tr>
<td>25</td>
<td>4.2</td>
<td>6.9</td>
</tr>
<tr>
<td>125</td>
<td>5.8</td>
<td>6.0</td>
</tr>
</tbody>
</table>

**Table 1: Intra-day and inter-day reproducibility of HPLC analysis of doxorubicin**

Plasma samples containing known amounts of doxorubicin were subjected to the acid extraction procedure and analyzed using HPLC and the inter-day and intra-day variation was checked.

### APPENDIX # 3

<table>
<thead>
<tr>
<th>Concentration of Doxorubicin added (ng/ml)</th>
<th>Concentration of Doxorubicin recovered</th>
<th>Percent recovery (mean ± standard deviation)</th>
</tr>
</thead>
<tbody>
<tr>
<td>25</td>
<td>23.3, 26.4, 23.9</td>
<td>98.1 ± 5.36</td>
</tr>
<tr>
<td>50</td>
<td>45.9, 48.1, 53.7</td>
<td>98.4 ± 6.56</td>
</tr>
<tr>
<td>100</td>
<td>94.5, 93.8, 96.7</td>
<td>95.0 ± 1.23</td>
</tr>
</tbody>
</table>

**Table 2: Efficiency of acid extraction method for recovery of Doxorubicin from mouse plasma**

Plasma samples were thawed and mixed using a vortex generator. One hundred milliliters of plasma were spiked with an equal volume of daunomycin (5 μM) as an internal standard and then mixed with 300 μl of 0.6 N HCl in 90% ethanol and stored at 4°C for one hour to form a gel. The sample was then centrifuged at 20,000 g for 25 minutes and the clear supernatant was analyzed for doxorubicin. Since doxorubicin and daunomycin are photosensitive, all manipulations were carried out under subdued light.
In figure 2: The influence of glucose on proliferation of MCF-7 and MCF-7/ADR cells in culture.
Plotted against doxorubicin concentration.

Survival of cells was reproducibly viable with respect to untreated controls.

Cells were treated with 10 to 12 days and then stained with 1% methylene blue in 50% ethanol, and the cultures were washed with phosphate buffered saline and then fixed.

After treatment, the medium containing the drug was removed, and the cultures were washed with phosphate buffered saline and resuspended in fresh medium. The cultures were observed for 10 to 12 hours after the drug was added to the cultures. The cultures were treated the next day with doxorubicin (0 to 20 μM) alone (open circle) or with tamoxifen (10 μM) (open circle) for 5 hours. At the end of the 5 hour drug treatment, the medium containing the drug was removed, and the cultures were washed with phosphate buffered saline and overnight. Cell viability was assessed using trypan blue exclusion.

Figure 3: Cell survival curves for MCF-7 cells treated with graded concentrations of doxorubicin with or without tamoxifen.

Doxorubicin (μM)

Percent relative survival

0

MCF-7 Cells

No Tamoxifen

Tamoxifen (10 μM)
controls was plotted against doxorubicin concentration.

Ethanol Ndlorous containing 50 or more cells were considered to be reproducibility viable. Survival of cells with respect to untreated

replicated with fresh medium. The cultures were incubated for 10 to 12 days and then stained with 1% methylene blue in 50%
drug-free medium: the medium containing the drug was removed and the cultures were washed with phosphate-buffered saline and

Drug-Free Medium (60-75 μM) alone (closed circle) or with tamoxifen (10 μM) (open circle) for 6 hours. At the end of the 6-hour

with doxorubicin (0.1-7.5 μM) alone (closed circle) or with tamoxifen (10 μM) (open circle) for 6 hours. At the end of the 6-hour

were plated in triplicate onto 60 x 15 mm dishes containing 5 ml complete medium. Cultures were fed the next day

Cell viability was assessed using clonogenicity measurements. Appropriate numbers of exponentially growing MCF-7/ADR cells

Figure 4: Cell survival curves for MCF-7/ADR cells treated with graded concentrations of doxorubicin.

Doxorubicin (μM)

Percent relative survival

75

50

25

10

0.1

1

10

100

TAMOXIFEN (10 μM)

No TAMOXIFEN

MCF-7/ADR Cells

APPENDIX # 6
(IC₅₀ of Doxorubicin in the presence of Tamoxifen)

(1) IC₅₀ of Doxorubicin in the absence of Tamoxifen

The enhancement index (EI) was calculated as the ratio and the survival assay was performed in a 96-well plate. The number of colonies was counted in triplicate and the ratio of colonies with or without drug was calculated.

Table 3: Enhancement of doxorubicin cytotoxicity by Tamoxifen

<table>
<thead>
<tr>
<th></th>
<th>MCF-7/ADR CELLS</th>
<th>MCF-7 CELLS</th>
</tr>
</thead>
<tbody>
<tr>
<td>IC₅₀</td>
<td></td>
<td></td>
</tr>
<tr>
<td>EI (EI)</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th></th>
<th>7.7</th>
<th>0.7</th>
<th>0.6</th>
<th>1.1</th>
<th>5.0</th>
<th>5.0</th>
</tr>
</thead>
<tbody>
<tr>
<td>Index (EI)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Enhancement</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Appropriate numbers of exponentially growing MCF-7 and MCF-7/ADR cells were plated in triplicate and grown for 60 x 15 mm.
Figure 5: Isobologram analysis of cell survival data on MCF-7 cells
The nature of the interaction of doxorubicin and tamoxifen was evaluated according to the method of Berenbaum (5). Since each

Figure 6: Isobologram analysis of cell survival data on MCF-7/ADR cells

Doxorubicin (micromolar)

TAMOXIFEN (micromolar)
The two cell lines differ in their tolerance of sensitivity to doxorubicin. Importantly, the concentration of doxorubicin used in these experiments cause reproductive death of almost all the cells. It is important to mention that the concentration of doxorubicin used in these experiments was higher in the case of MCF-7/ADR cells compared to MCF-7/ADR cells. The signal due to doxorubicin semiquinone was higher in the case of MCF-7/ADR cells. Inclusion of ammonium (10 mM) did not affect the formation of semiquinone reductase signal. The intensity of the formation of the anhydride semiquinone was higher over 60 minutes period in order to assess the kinetics of semiquinone formation. The relative intensity of the anhydride semiquinone was recorded.

Single cell suspensions were prepared from exponentially growing monolayer cultures. Anaerobic incubations were carried out in a closed system. Vials (2 ml capacity) containing 0.17 ml medium in phosphate buffered saline (pH 7.4), glucose (0.2 mM), and doxorubicin (0.1 mM) were transferred anaerobically into an ESR sample container at 37°C and the spectra recorded.

**Figure 7:** Comparison of doxorubicin semiquinone free radical production during anaerobic metabolism.

**Time (minutes):**

60 45 30 15 0

**Relative intensity of semiquinone signal:**

- MCF-7/ADR+DOX+Tam
- MCF-7/ADR+DOX+Tam
- MCF-7/ADR
- MCF-7/ADR+Tam
- MCF-7/ADR+Tam

Appendix # 10
The intensity of the second peak of the DMP-OH signal was plotted against duration of incubation. Incubation mixture maintained at 37°C. Electron spin resonance spectra were acquired at different times over a period of 1 hour. For these experiments, aerobic incubation mixtures containing 10⁷ cell per ml in phosphate buffer (pH 7.4), glucose (2 mM), doxorubicin (100 µM) and DMP (100 µM) with or without tamoxifen (10 µM). 

Figure 8: Comparison of hydroxyl free radical production in aerobic incubations of MCF-7 and MCF-7/ADR+DOX with or without tamoxifen.
Figure 9: Inhibition of cardiac microsomal lipid peroxidation by tamoxifen.

Inhibition mixtures contained 3 mg microsomal protein per ml, 2.5 mM NADPH with or without doxorubicin (25 pM) and tamoxifen.

Malondialdehyde (nmol/mg protein)

Heart microsomes

NADPH

NADPH + DOX (25 pM)
Proceed at 37°C for 60 minutes in the presence or absence of doxorubicin (25 µM) with or without tamoxifen (10 µM).

Figure 10: Influence of tamoxifen on doxorubicin-induced lipid peroxidation in liver microsomes.

Tamoxifen (µM)

Liver microsomes

Malondialdehyde (nmoles/mg protein)
the extent of peroxidation was assessed by measuring dihydroxyacetone and diol reaction products. Lipid peroxidation was allowed to proceed for 60 minutes at 37°C and concentrations of 1 mg of microsomal protein per ml and 0.5 mg NADPH in a reaction mixture containing 1 ml of microsomal lipids and 0.1 ml of 0.5 mM NADPH.

**Figure 11: Effect of doxorubicin concentration on microsomal lipid peroxidation.**
APPENDIX # 15


A920 CARCINOGENESIS—OTHER DIETARY COMPONENTS (682.11-682.14) TUESDAY AM

682.14

MCF-7 AND MCF-7/ADR CELLS RESPOND DIFFERENTLY TO CHANGES IN GLUCOSE CONCENTRATIONS. B. Siddar, M. Yamamoto, N.A. Patel and D.R. Cooper, Howard Univ. Hospital and Cancer Center, Washington, DC 20060 and Univ. of South Florida College of Medicine and J.A. Haley Veterans Hospital, Tampa, FL 33612.

Glucose is a major source of energy in tumor cells and diabetes may be a risk factor for breast cancer and endometrial cancer. The human breast cancer cell line MCF-7 and its multidrug resistant variant MCF-7/ADR differ in their response to changes in glucose concentrations in the culture medium. A shift of glucose concentration from normal (5.5 mM) to high (25.0 mM) levels caused an increase in DNA synthesis and proliferation of MCF-7 cells but not MCF-7/ADR cells in monolayer cultures. High glucose induced decreases in PKC-BII protein and mRNA levels during DNA synthesis phase in MCF-7 cells but not in MCF-7/ADR cells. The levels of protein kinase C-βII (PKC-βII) protein and the corresponding mRNA levels were 3 to 4 fold higher in MCF-7/ADR cells compared to MCF-7 cells, but were not down regulated by high glucose. These results indicate a possible role of PKC-BII as a regulator of the cell cycle in MCF-7 cells cultured in medium containing high glucose concentration.

Supported by USAMRAA grant DAMD 17-98-1-8109 (RS3), Department of Veterans Affairs and NSF MCB-9725935 (DRG) and Uehara Memorial Foundation (MY)